Disease Domain | Count |
---|---|
Immune System Diseases | 4 |
Endocrinology and Metabolic Disease | 2 |
Neoplasms | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 3 |
Fusion protein | 1 |
Target |
Mechanism IL-17A inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IGF-1R antagonists |
Active Org. ValenzaBio, Inc.Startup |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism c-Kit inhibitors |
Active Org. |
Originator Org. ValenzaBio, Inc.Startup [+1] |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Jun 2023 |
Sponsor / Collaborator |
Start Date25 Apr 2023 |
Sponsor / Collaborator |
Start Date14 Feb 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Izokibep ( IL-17A x albumin ) | Hidradenitis Suppurativa More | Phase 3 |
VB-421 ( IGF-1R ) | Graves Ophthalmopathy More | Phase 2 Clinical |
Lonigutamab ( IGF-1R ) | Graves Ophthalmopathy More | Phase 1 |
VB-517 ( c-Kit ) | Chronic Urticaria More | Phase 1 |